## **New Claims**

- 1 -- 120. A composition comprising a cocoa procyanidin monomer and/or oligomer and a
- 2 carrier selected from the group consisting of a pharmaceutically acceptable carrier, veterinary
- acceptable carrier, dietary supplement carrier and food, wherein said composition is packaged
- with instructions directing use of the composition as an anti-inflammatory agent.
- 1 121. The composition of claim 120, wherein the cocoa procyanidin is a dimer.
- 1 122. The composition of claim-120, wherein the cocoa procyanidin is at least one of
- 2 oligomers 3-12 or any mixture thereof.
- 1 123. The composition of claim 120, wherein the cocoa monomer and/or oligomer is in
- 2 the form of a cocoa extract or cocoa procyanidin-containing fraction thereof.
- 1 124. The composition of claim 120, wherein the monomer comprises epicatechin and
- 2 the oligomer comprises an epicatechin-containing oligomer.
- 1 125. The composition of claim 120, wherein the carrier is a pharmaceutically
- 2 acceptable caprier.
- 1 126./ The composition of claim 120, wherein the carrier is a veterinary acceptable
- 2 carrier



- 1 127. The composition of claim 120, wherein the carrier is a food.
- 1 128. The composition of claim 120, which is a dietary supplement.
- 1 129. The packaged composition of claim 120, further comprising a cyclo-oxygenase modulator.
- 1 130. The packaged composition of claim 129, wherein the cyclo-oxygenase modulator
- 2 is a non-steroidal anti-inflammatory drug
- 1 131. The packaged composition of claim 130, wherein the non-steroidal anti-
- 2 inflammatory drug is an aspirin.
  - A composition comprising a cocoa procyanidin monomer and/or oligomer and a carrier selected from the group consisting of a pharmaceutically acceptable carrier, veterinary acceptable carrier, dietary supplement carrier and food, wherein said composition is packaged with instructions directing use of the composition as an antiplatelet therapy.
- 1 133. The composition of claim 132, wherein the cocoa procyanidin is a dimer.
- 1 134. The composition of claim 132, wherein the cocoa procyanidin is at least one of
- 2 oligomers 3-12 or any mixture thereof.

142.

is a non-steroidal anti-inflammatory drug.

1

2

The packaged composition of claim 141, wherein the cyclo-oxygenase modulator

1	143.	The packaged composition of claim 142, wherein the non-steroidal anti-
2	inflamm	natory drug is an aspirin.
1	144.	A composition comprising a cocoa procyanidin monomer and/or oligomer and a
2	carrier s	elected from the group consisting of a pharmaceutically acceptable carrier, veterinary
3	acceptab	ole carrier, dietary supplement carrier and food, wherein said composition is
4	package	d with instructions directing use of the composition as an agent for improving or
5		ning vascular health.
1	145.	The composition of claim 144, wherein the cocoa procyanidin is a dimer.
1	146.	The composition of claim 44, wherein the cocoa procyanidin is at least one of
2	oligomer	rs 3-12 or any mixture thereof.
1	147.	The composition of claim 144, wherein the cocoa monomer and/or oligomer is in
2	the form	of a cocoa extract or cocoa procyanidin-containing fraction thereof.
1	148.	The composition of claim 144, wherein the monomer comprises epicatechin and
2	the oligon	mer comprises an epicatechin-containing oligomer.
1	149.	The composition of claim 144, , wherein the carrier is a pharmaceutically
2	acceptabl	carrier.
·		AMENDMENT mailed January 3, 2002 U.S. Appl. Ser. No. 09/459,171 Filed December 10, 1999 NYB 1307880.1

1	150.	The composition of claim 144, wherein the carrier is a veterinary acceptable
2	carrier.	
1	151.	The composition of claim 144, wherein the carrier is a food.
1	152.	The composition of claim 144, which is a dietary supplement.
1	153.	A composition comprising a cocoa procyanidin monomer and/or oligomer and a
2	carrier sel	ected from the group consisting of a pharmaceutically acceptable carrier, veterinary
3	acceptable	carrier, dietary supplement carrier and food, wherein said composition is
4	packaged	with instructions directing use of the composition for at least one of the following:
5	modulatin	g nitric oxide synthesis, inducing vasodilation, modulating renal function, and
6	reducing b	plood pressure.
1	154.	The composition of claim 153, wherein the cocoa procyanidin is a dimer.
1	155.	The composition of claim 153, wherein the cocoa procyanidin is at least one of
2	oligomers	3-12 or any mixture thereof.
1	156.	The composition of claim 153, wherein the cocoa monomer and/or oligomer is in
2	the form o	f a cocoa extract or cocoa procyanidin-containing fraction thereof.

1	157.	The composition of claim 153, wherein the monomer comprises epicatechin and
2	the oligor	ner comprises an epicatechin-containing oligomer.
1	158.	The composition of claim 153, , wherein the carrier is a pharmaceutically
2	acceptabl	e carrier.
/		
1	159.	The composition of claim 153, wherein the carrier is a veterinary acceptable
2	carrier.	
1	160.	The composition of claim 153, wherein the carrier is a food.
1	161.	The composition of claim 153, which is a dietary supplement.
1	162.	A composition comprising a cocoa procyanidin monomer and/or oligomer and a
2	carrier se	lected from the group consisting of a pharmaceutically acceptable carrier, veterinary
3	acceptabl	e carrier, dietary supplement carrier and food, wherein said composition is
4	packaged	with instructions directing use of the composition for at least one of the following:
5	reducing	the risk of thrombosis, treating or preventing atherosclerosis, and treating or
6	(	g restenosis.
1	163.	The composition of claim 162, wherein the cocoa procyanidin is a dimer.

1	164.	The composition of claim 162, wherein the cocoa procyanidin is at least one of
2	oligomer	s 3-12 or any mixture thereof.
1	165.	The composition of claim 162, wherein the cocoa monomer and/or oligomer is in
2	the form	of a cocoa extract or cocoa procyanidin-containing fraction thereof.
1	166.	The composition of claim 162, wherein the monomer comprises epicatechin and
2	the oligon	mer comprises an epicatechin-containing oligomer.
1	167.	The composition of claim 162, wherein the carrier is a pharmaceutically
2	acceptabl	e carrier.
1	168.	The composition of claim 162, wherein the carrier is a veterinary acceptable
2	carrier.	
1	169.	The composition of claim 162, wherein the carrier is a food.
1	170.	The composition of claim 162, which is a dietary supplement.
1	171.	A composition comprising a cocoa procyanidin monomer and/or oligomer and a
2	carrier sel	ected from the group consisting of a pharmaceutically acceptable carrier, veterinary
3	acceptable	e carrier, dietary supplement carrier and food, wherein said composition is
4	packaged	with instructions directing use of the composition for treating hypertension.

AMENDMENT mailed January 3, 2002 U.S. Appl. Ser. No. 09/459,171 Filed December 10, 1999 NYB 1307880.1

The composition of claim 171, wherein the cocoa procyanidin is a dimer. 172. 1 The composition of claim 171, wherein the cocoa procyanidin is at least one of 1 173. 2 oligomers 3-12 or any mixture thereof. The composition of claim 171/wherein the cocoa monomer and/or oligomer is in 174. the form of a cocoa extract or cocoa procyanidin-containing fraction thereof. 175. The composition of claim/171, wherein the monomer comprises epicatechin and 1 the oligomer comprises an epicatechin-containing oligomer. 2 The composition of claim 171, wherein the carrier is a pharmaceutically 176. 1 acceptable carrier. 2 177. The composition  $\phi$ f claim 171, wherein the carrier is a veterinary acceptable 1 2 carrier. 1 178. The composition of claim 171, wherein the carrier is a food. 179. 1 The composition of claim 171, which is a dietary supplement. A composition comprising a cocoa procyanidin monomer and/or oligomer in 1 180. 2 admixture with a cyclo-oxygenase modulator.

> AMENDMENT mailed January 3, 2002 U.S. Appl. Ser. No. 09/459,171 Filed December 10, 1999 NYB 1307880.1

1	181.	The composition of claim 180, wherein the cyclo-oxygenase modulator is a non-
2	steroida	ıl anti-inflammatory drug.
1	182.	The composition of claim 181, wherein the non-steroidal anti-inflammatory drug
2	is an asj	pirin.
1	183.	The composition of claim 180, wherein the cocoa procyanidin is a dimer.
1	184.	The composition of claim 180, wherein the cocoa monomer and/or oligomer is in
2	the form	of a cocoa extract of cocoa procyanidin-containing fraction thereof.
1	185.	The composition of claim 180, wherein the monomer comprises epicatechin and
2	the oligo	omer comprises an epicatechin-containing oligomer.
1	186.	A method of treating hypertension by administering a composition comprising a
2	cocoa pr	ocyanidin monomer and or oligomer and a carrier selected from the group consisting
3	of a phai	rmaceutically acceptable carrier, veterinary acceptable carrier, dietary supplement
4	carrier a	nd food to a subject suffering from hypertension, wherein said subject is a human or
5	a veterin	ary animal.
1	187.	The method of claim 186, wherein said subject is a human.
1	188.	The method of claim 186, wherein the cocoa procyanidin is a dimer.

AMENDMENT mailed January 3, 2002 U.S. Appl. Ser. No. 09/459,171 Filed December 10, 1999 NYB 1307880.1

The composition of claim 186, wherein the cocoa monomer and/or oligomer is in 189. 1 the form of a cocoa extract or cocoa procyanidin-containing fraction thereof. 2 190. The composition of claim 186, wherein the monomer comprises epicatechin and 1 the oligomer comprises an epicatechin-containing oligomer. The method of claim 186, wherein the cocoa procyanidin is at least one of 191. oligomers 3-12 or any mixture thereof. 192. 1 The method of claim 191, wherein the carrier is a pharmaceutically acceptable 2 carrier. 193. The method of claim 186 wherein the carrier is a food. 1 194. A method of anti-platelet therapy or prophylaxis comprising administering to a 1 2 subject in need thereof a composition comprising a cocoa procyanidin monomer and/or 3 oligomer and a carrier selected from the group consisting of a pharmaceutically acceptable 4 carrier, veterinary acceptable carrier, dietary supplement carrier and food, wherein said 5 subject is a human or a veterinary animal.

The method of claim 194, wherein said subject is a human.

The method of claim 194, wherein the cocoa procyanidin is a dimer.

195.

196.

1

1

- The composition of claim 194, wherein the cocoa monomer and/or oligomer is in 197. 1 the form of a cocoa extract or cocoa procyanidin-containing fraction thereof. 2 The composition of claim 194, wherein the monomer comprises epicatechin and 198. 1 the oligomer comprises an epicatechin-containing oligomer. The method of claim 194, wherein the cocoa procyanidin is at least one of 199. oligomers 3-12 or any mixture thereof. 1 200. The method of claim 199, wherein the carrier is a pharmaceutically acceptable 2 carrier. 201. The method of claim 194 wherein the carrier is a food. 1
- 1 203. The method of claim 202, wherein the cyclo-oxygenase modulator is a non-

The method of claim 194 further comprising administering to the subject a cyclo-

2 steroidal anti-inflammatory drug.

oxygenase modulator.

- 1 204. The method of claim 203, wherein the non-steroidal anti-inflammatory drug is an
- 2 aspirin.

202.

1

2

1	205.	A method of treating, reducing the risk of, or preventing atherosclerosis,
2	thrombos	is, restenosis, heart attack or stroke comprising administering to a subject in need
3	thereof a	composition comprising a cocoa procyanidin monomer and/or oligomer and a
4	carrier sel	ected from the group consisting of a pharmaceutically acceptable carrier, veterinary
5	acceptable	e carrier, dietary supplement carrier and food, wherein said subject is a human or a
6	veterinary	animal.
1	206.	The method of claim 205, wherein said subject is a human.
1	207.	The method of claim/205, wherein the cocoa procyanidin is a dimer.
1	208.	The composition of claim 205, wherein the cocoa monomer and/or oligomer is in
2	the form of	of a cocoa extract or cocoa procyanidin-containing fraction thereof.
1	209.	The composition of claim 205, wherein the monomer comprises epicatechin and
2	the oligon	ner comprises an epicatechin-containing oligomer.
1	210.	The method of claim 209, wherein the cocoa procyanidin is at least one of
2	oligomers	β-12 or any mixture thereof.
1	211.	The method of claim 210, wherein the carrier is a pharmaceutically acceptable
2	carrier.	

1	212.	The method of claim 205, wherein the carrier is a food.
1	213.	The method of claim 205, further comprising administering to the subject a cyclo-
2	oxygena	se modulator.
( 1	214.	The method of claim 213, wherein the cyclo-oxygenase modulator is a non-
2	steroidal	anti-inflammatory drug.
1	215.	The method of claim 2 4, wherein the non-steroidal anti-inflammatory drug is an
2	aspirin.	
1	216.	A method of treating or reducing the progression of a condition associated with
2	inflamma	ation comprising administering to a subject in need thereof a composition
3	comprisi	ng a cocoa procyanidin monomer and/or oligomer and a carrier selected from the
4	group co	nsisting of a pharmaceutically acceptable carrier, veterinary acceptable carrier,
5	dietary sı	applement carrier and food, wherein said subject is a human or a veterinary animal.
1	217.	The method of claim 216, wherein said subject is a human.
1	218.	The method of claim 217, wherein the condition associated with inflammation is
2	at least or	ne of the following: inflammatory bowel disease, ulcerative colitis, Chron's disease,
3	gingivitis	, acute edema, thronic arthritis, and spondylitis.

	1	220.	The composition of claim 216, wherein the cocoa monomer and/or oligomer is in
	2	the form of	of a cocoa extract or cocoa procyanidin-containing fraction thereof.
$\lambda^{\prime}$	)	221.	The composition of claim 216, wherein the monomer comprises epicatechin and
PM	2	the oligon	ner comprises an epicalechin-containing oligomer.
(M)	•		
O	1	222.	The method of claim 216, wherein the cocoa procyanidin is at least one of
	2	oligomers	3-12 or any mixture thereof.
	1	223.	The method of claim 222, wherein the carrier is a pharmaceutically acceptable
	2	carrier.	
	İ		
	1	224.	The method of claim 216 wherein the carrier is a food
-			V

The method of claim 216, wherein the cocoa procyanidin is a dimer.

219.

1

ATTACHMENT 1

## Attachment I

Cancelled Claims	New Claims
34	120
35	121
122	36
-	123
-	124
37	125
38	126
39	127
40	128
41	129
42	130
43	131
44	132
45	133
46	134
-	135
-	136
47	137
48	138
49	139
50	140

Cancelled Claims	New Claims
51	141
52	142
53	143
54	144
55	145
56	146
-	147
	148
57	149
58	150
59	151
60	152
61	153
62	154
63	155
-	156
-	157
64	158
65	159
66	160
67	161
68	162
69	163
70	164

Cancelled Claims	New Claims
-	165
-	166
71	167
72	168
73	169
74	170
-	171
-	172
-	173
-	174
-	175
-	176
-	177
-	178
-	179
75	180
76	181
77	182
78	183
-	184
-	185
87	186
88	187
89	188

New Claims
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212

Cancelled Claims	New Claims
108	213
109	214
110	215
111	216
112	217
113	218
114	219
	220
-	221
115	222
116	223
117	224